MedPath

Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Phase 3
Recruiting
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
First Posted Date
2024-01-08
Last Posted Date
2024-03-07
Lead Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Target Recruit Count
490
Registration Number
NCT06194734
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase 3
Recruiting
Conditions
Ganglioneuroblastoma, Nodular
Neuroblastoma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Cyclophosphamide
Biological: Dinutuximab
Drug: Doxorubicin
Drug: Etoposide
Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan
Procedure: Hematopoietic Cell Transplantation
Drug: Irinotecan
Drug: Isotretinoin
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Drug: Melphalan
Radiation: Radiation Therapy
Procedure: Radionuclide Imaging
Other: Survey Administration
Drug: Temozolomide
Drug: Thiotepa
Drug: Topotecan
Procedure: Tumor Resection
Drug: Vincristine
First Posted Date
2023-12-15
Last Posted Date
2025-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
478
Registration Number
NCT06172296
Locations
🇺🇸

USA Health Strada Patient Care Center, Mobile, Alabama, United States

🇺🇸

Mercy Hospital Saint Louis, Saint Louis, Missouri, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 123 locations

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

Recruiting
Conditions
Fruquintinib
Irinotecan
Capecitabine
Gastrointestinal Tumours
Interventions
First Posted Date
2023-12-13
Last Posted Date
2023-12-13
Lead Sponsor
China Medical University, China
Target Recruit Count
50
Registration Number
NCT06169202
Locations
🇨🇳

First Hospital of China Medical University, Shenyang, Liaoning, China

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Phase 2
Not yet recruiting
Conditions
Previously AG Chemotherapy Treated Pancreatic Cancer
Interventions
First Posted Date
2023-12-12
Last Posted Date
2023-12-12
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
19
Registration Number
NCT06166589
Locations
🇨🇳

Zhongshan Hospital, Shanghai, Shanghai, China

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

First Posted Date
2023-11-18
Last Posted Date
2024-12-20
Lead Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Target Recruit Count
186
Registration Number
NCT06139211
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Phase 2
Recruiting
Conditions
Unresectable Metastatic Colorectal Cancer
Interventions
First Posted Date
2023-10-30
Last Posted Date
2024-12-24
Lead Sponsor
AbbVie
Target Recruit Count
206
Registration Number
NCT06107413
Locations
🇺🇸

Highlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States

🇺🇸

City of Hope National Medical Center /ID# 257576, Duarte, California, United States

🇺🇸

Northwestern University Robert H. Lurie Comprehensive Cancer Center /ID# 260563, Chicago, Illinois, United States

and more 34 locations

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Phase 2
Active, not recruiting
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2023-10-23
Last Posted Date
2024-12-03
Lead Sponsor
Australasian Gastro-Intestinal Trials Group
Target Recruit Count
20
Registration Number
NCT06094140
Locations
🇦🇺

GenesisCare North Shore, Sydney, New South Wales, Australia

🇦🇺

Wollongong Hospital, Wollongong, New South Wales, Australia

🇦🇺

Warringal Private Hospital, Melbourne, Victoria, Australia

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Phase 2
Not yet recruiting
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
First Posted Date
2023-10-18
Last Posted Date
2023-10-18
Lead Sponsor
Shanghai JMT-Bio Inc.
Target Recruit Count
102
Registration Number
NCT06089330

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

First Posted Date
2023-08-28
Last Posted Date
2023-09-21
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
30
Registration Number
NCT06013618
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Early Phase 1
Recruiting
Conditions
Colo-rectal Cancer
Interventions
Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Fluorouracil
Drug: Irinotecan
Biological: Cetuximab
Biological: Bevacizumab
Procedure: Metastasectomy
Procedure: Biospecimen collection
Procedure: Computed Tomography
Biological: Panitumumbab
First Posted Date
2023-08-25
Last Posted Date
2024-05-03
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
42
Registration Number
NCT06011772
Locations
🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath